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Abstract
Although it seems reasonable to suggest that most women experience significant changes in quality of life
(QOL) during the menopausal period, few researchers have quantified these changes. A total of 1497
women, aged 40–54 years and living on the island of Kinmen, were recruited for this survey. However, 137
were eliminated leaving 1360 for analysis. Women who used hormonal therapy or who had undergone
surgically induced menopause were excluded. The subjects with incomplete data or who exhibited mental
retardation or severe psychiatric disease were also eliminated. Univariate analysis demonstrated that, in
general, QOL scores were poorer for perimenopausal and postmenopausal status. Comparing pre- and
postmenopausal women, significant statistical differences were demonstrated for role limitations due to
physical and emotional problems, even after adjusting for age, education level, body mass index, menarche,
and chronic illness. A strong association was demonstrated between menopausal symptoms and premens-
trual syndrome (PMS). Women with menopausal symptoms and PMS had significantly lower scores on all
SF-36 dimensions. The results of this study suggest that poorer health status is experienced by peri- and
postmenopausal women compared to premenopausal women.
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Introduction
Quality of life (QOL) is a multidimensional health
concept, which represents mainly subjective
symptoms that may influence the sense of well-
being and day-to-day function. It includes several
important domains, such as perceived well-being,
role disability, and physical, psychological and
social function. Women may experience significant
QOL changes during menopause, and only a few
researchers have quantified these changes [1–3].
Daly et al. [1] have even proposed that QOL
is severely compromised by the presence
of menopausal symptoms, indicating that the ef-
fects of these symptoms may have been underes-
timated.
The impact of menopause on QOL could be
a consequence of biological changes, associated
symptoms, and/or sociocultural factors. Several
studies have demonstrated that hormone replace-
ment therapy (HRT) improves QOL scores [4–7].
Nevertheless, relatively few studies have explored
the effects of menopause per se on QOL [2, 3]. So-
ciocultural factors may also affect the menopausal
transition experience [8]. Studies of Asian samples
[9, 10] indicate that the prevalence of vasomotor
symptoms is markedly lower for these populations
compared Western population. As menopausal
experience differs for these populations compared
to Western populations, cross-cultural studies may
yield more information clarifying the relationship
between menopause and QOL.
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Implementation of a valid and accurate QOL
instrument is also very important for producing
more precise information and to enable better
verification of statistical relationships. Although
there is no gold standard for QOL measurement, a
number of self-administered QOL instruments [11,
12] have been developed over the last 20 years and
broadly applied to health-services research and
clinical trials. Utilization of a well-known standard
questionnaire for QOL evaluation will facilitate
interpretation and comparison of results obtained
from different studies throughout the world.
This research was part of a larger program in-
vestigating women’s health and menopause. In this
cross-sectional study of middle-aged women, we
examined the relationship between QOL scores,
menopause, and associated symptoms, using a
validated instrument – the Medical Outcomes
Study Short Form-36 (SF-36) [12, 13].
Methods
Kinmen Women’s-Health Investigation
Kinmen is a 176-km2 island that is 248 km
(154 miles) west of Taiwan and 41 km (25 miles)
east of mainland China. It consists of four town-
ships with a total population of 51,060 people
(1998). The populace is served by two public
hospitals and 31 physicians. The people of Kinmen
are Han Chinese, most of whom are involved in
farming activities or small business. There is no
modern industry. Kinmen remained in close con-
tact with China from the fourth century until the
Japanese occupation in 1937. The government of
the Republic of China reigned over the island
again from 1945; however, it was under military
control after the government moved to Taiwan in
1949. Kinmen became a popular tourist destina-
tion after martial law was lifted in 1993. Most of
the people on Kinmen retain a traditional Chinese
lifestyle, and living standards are similar to the
rural areas of southern Taiwan.
There are four townships in Kinmen, with sim-
ilar demographic compositions. Based on logistic
convenience, Kin-Hu and Kin-Cheng were chosen
for the study. From 1998 registration records,
there were 2256 women aged 40–54 living in these
two townships. This was the target population for
the present study, and no sampling frame was
used.
The Kinmen Women’s-Health Investigation
(KIWI) cohort was established in 1998. The study
protocol was approved by the institutional review
board of the Taipei Veterans General Hospital.
Further details of the KIWI have been described
elsewhere [13, 14].
Medical Outcomes Study Short Form-36 (SF-36)
Health Survey
The SF-36 questionnaire was originally developed
for the Rand Corporation’s Health Insurance
Experiment [11]. Its reliability and validity have
been tested in Taiwan [13]. It is a self-adminis-
tered, 36-item questionnaire that measures health-
related function in eight domains, including
physical functioning, role limitations due to
physical and emotional problems, vitality, bodily
pain, social functioning, mental health, and gen-
eral health perceptions. After summing the Likert-
scale items that make up SF-36, each scale was
then standardized to range from 0 (lowest level of
function) to 100 (highest level) [11]. As a general
guide, Ware et al. [11] have suggested that a de-
crement of five points or more, for any of the SF-
36 scales, is clinically relevant. Translation for a
Taiwanese version of SF-36 was developed using
standard methodology as detailed in the IQOLA
Project [15]. The discriminative item validity was
high for all subscales and Cronbach’s a reliabilities
were above 0.70 criterion with exception of two
subscales [13].
Other questionnaires
Additional study instruments included common
sociodemographic questionnaires, a menopause-
related symptom checklist, the hospital anxiety
and depression scale (HADS) [16, 17] and history
of chronic illness. The height and weight of all the
patients were measured, and the body mass index
(BMI; calculated as weight (kg) divided by height
(m) squared).
The menopause-related symptom checklist
(symptoms experienced during the 2 weeks prior
to the study) was a modification of the Kupper-
man index [18]. It included complaints of hot
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flushes, night sweating, dizzy spells, headaches,
insomnia, fatigue, arthralgia, myalgia, backaches,
vaginal dryness and frequent urination.
The participants were also asked about their
menstrual and reproductive history including the
PMS. (‘Do you or did you suffer from PMS?’) A
number of questions investigating premenstrual
symptoms experienced were also included to
screen for PMS. PMS was defined based on the
Tenth Revision of the International Classification
of Diseases (ICD-10) as a history of at least one
physical or mood symptom occurring in a cyclic
fashion, that is, present during the last week before
menses and absent in the week postmenses [19, 20].
These seven symptoms included minor psycho-
logical discomfort, bloating or weight gain, breast
tenderness, muscular tension, aches and pains,
poor concentration, and change in appetite.
The HADS was developed and validated using
non-psychiatric patients [16, 17]. Items relating to
both mood disorders and physical illnesses were
omitted for the current study. The modified in-
strument consisted of 14 questions, seven for
anxiety and seven for depression. Compared to
general practitioners, superior diagnostic perfor-
mance was demonstrated for detection of anxiety
and depression. Scores range from 0 to 42. The
Cronbach’s a coefficient of Chinese HADS was
0.84 [17]. The optimal cut-off points of the HADS
were a depression score of 6 and an anxiety score
of 3. The sensitivity was 80% and specificity was
90% [21].
The presence of chronic illness was assessed
using 10 yes-or-no questions (for diabetes, hyper-
tension, epilepsy, cancer, stroke, lung, liver, and
renal disease, arthritis and other heart disease).
Definition of menopausal status
Menopausal status was classified as pre-, peri- or
postmenopausal. The premenopausal period was
defined by regular menstruation. A woman was
considered perimenopausal if her menstrual cycles
had been irregular or her last menstrual bleeding
occurred more than three but less than or equal to
12 months prior to the study. Women who had
not menstruated within the previous 12 months
were categorized as postmenopausal. Those who
used HRT or had surgically induced menopause
were excluded from this study.
Data analysis
The SF-36 results were considered usable when
respondents answered at least half of the items for
each scale. When some (but fewer half) of the in-
dividual answers for a given scale were missing, the
imputation method recommended by Ware et al.
[11] was used to replace the missing items using the
mean derived from other available scale items. For
the present study, however, imputed scale scores
were derived for only 0.7% of the respondents.
Kruskal–Wallis statistics and generalized linear
models were used to compare QOL scores between
menopausal status groups with and without ad-
justment for age, education, BMI, menarche, and
presence of chronic illness.
Menopausal symptoms were analysed using two
approaches. One involved the presence of indi-
vidual symptoms, the other combined symptoms
into four dummy categories: vasomotor (hot
flushes, night sweats); psychosomatic (dizzy spells,
headaches, insomnia, fatigue), physical (arthralgia,
myalgia, backaches), and urovaginal (vaginal
dryness, frequent urination). The v2 test was used
to assess the association between each pair of
individual menopausal symptoms as well as the
association between individual menopausal symp-
toms and menopausal status. The relationship
between each menopausal-symptom category and
QOL score was assessed using the Wilcoxon rank-
sum test. Further, to test the impact of meno-
pausal symptoms on QOL score while controlling
for menopausal status, the Wilcoxon rank-sum
tests were performed separately for each meno-
pausal status using the Bonferroni adjustment for
the Type I-error rate.
The frequency distribution of menopausal
symptoms was compared across PMS status
groups using the v2 test. The QOL scores were
compared between women who experienced and
did not experience PMS discomfort using the
Wilcoxon rank-sum test. Furthermore, the same
analysis was performed to test the influence of
menopausal-symptom categories on QOL score
while controlling for PMS. Additionally, the im-
pact of PMS on menopausal symptoms was ex-
pressed using the odds ratio with 95% confidence
interval.
All statistical tests were two sided. A p-value of
0.05 or less was considered statistically significant.
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The Bonferroni adjustment was used for pairwise
comparison.
Results
Characteristics of the study population
Of the 2256 targeted subjects, a total of 1497
(66%) participated in the study. The remaining
759 were not included for the following reasons:
(1) not at home on each of the three house calls
(n ¼ 634); (2) refused to participate (n ¼ 88); and
(3) did not receive invitation due to mail-delivery
failure (n ¼ 37). For the final analysis, 56 subjects
with incomplete data were excluded, as were five
who exhibited mental retardation or severe psy-
chiatric illness, and 76 women who had undergone
hysterectomy or HRT during the preceding
6 months. The final sample size was 1360.
Table 1 presents the demographic and other
characteristics for enrolled patients by menopausal
status. Menopausal-status distribution was 734
(54%), 363 (27%), and 263 (19%) for pre-, peri-
and postmenopause, respectively. Seventy-six per-
cent of the postmenopausal women were within
the first 3 years of menopause. The mean age was
45.4 years (SD: 4.0; range: 40–54) with a highly
significant difference demonstrated for all pairwise
menopausal-status comparisons (p < 0:0001).
Similarly, significant BMI differences were deter-
mined comparing pre- and perimenopause, and
pre- and postmenopause. No significant differ-
ences were demonstrated between age at menarche
and menopausal status, however. Of the other
demographic variables studied, a significant rela-
tionship with menopausal status was only dem-
onstrated for education.
Impact of menopause on QOL score
The SF-36 scores for different menopausal status
groups are presented in Table 2. Except for social
functioning, QOL scores were highest for pre-
menopausal status and lowest for the postmeno-
pausal women. Pairwise comparison indicated that
the difference in QOL score was significant for
physical functioning and role limitation due to
physical problem comparing pre- and perimeno-
pause (p ¼ 0:0001 and 0.005, respectively), and
between pre- and postmenopause (p ¼ 0:002 and
0.0002, respectively). The biggest difference from
pre- to postmenopause was demonstrated for role
limitation due to physical problem (mean differ-
ence 8.8, CI [3.9, 13.6]), followed by role limitation
due to emotional problem (mean difference 5.2, CI
[0.5, 10.0]), and general health perception (mean
difference 4.6, CI [1.7, 7.6]) in that postmenopausal
women had lower scores than those who were
premenopausal. Statistical significance was not
demonstrated for any of these differences between
premenopausal and perimenopausal status, how-
Table 1. Demographic and other characteristics of the study population according to menopausal status
Premenopausal N=734 Perimenopausal N=363 Postmenopausal N=263
Age (years)a,b,c,d 43.6 (2.9) 46.1 (3.7) 49.4 (3.8)
Education (years)a,b,c,d 6.9 (4.3) 6.0 (4.5) 4.3 (4.2)
BMI (SD) a,b,c 23.9 (3.4) 24.4 (3.8) 24.6 (3.6)
Age at menarche (years)a 15.4 (1.6) 15.6 (1.9) 15.7 (1.8)
% illiteratee,f 22.2% 33.9% 51.3%
% chronic illnesse 16.4% 25.5% 28.6%
% smoking habite 1.5% 1.1% 0%
% alcohol drinking habite 9.1% 7.4% 7.2%
aStatistical analysis was performed using the Kruskal–Wallis test with Bonferroni’s correction for multiple comparisons. The number
for age, education, BMI, age at menarche represent the mean and standard deviation. A p-value of less than or equal to 0.017 was
considered to be statistically significant.
b Significant difference between pre- and perimenopause.
c Significant difference between pre- and postmenopause.
d Significant between peri- and post-menopause.
e Statistical analysis using v2 test.
f A p-value of less than or equal to 0.05 was considered statistically significant.
BMI – body mass index.
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ever. In addition, total HADS scores did not differ
significantly between any of the three groups.
After controlling for age, education level, BMI,
menarche, and their interactions, it was determined
that the presence of chronic illness masked the in-
fluence of menopause on QOL score, accounting
for the lack of significant difference in SF-36 scores
between menopausal status groups. On the other
hand, significant differences were demonstrated
for role limitation due to physical and emotional
problems, and general health perceptions scores
comparing different menopausal status groups for
women without chronic illness (p < 0:0001, p ¼
0:02, and p ¼ 0:02, respectively). Further, ad hoc
pairwise comparisons revealed differences for gen-
eral health perception pre- and perimenopause,
role limitation due to emotional problem pre- and
postmenopause, and, role limitation due to physi-
cal problem pre- and postmenopause and peri- and
postmenopause (p < 0:017).
Menopausal symptoms and SF-36 score
All menopausal symptoms were strongly associ-
ated with each other (except for the association
between vaginal dryness and headaches (p ¼
0:04)). Furthermore, women with vasomotor
symptoms were more likely to have insomnia
problems (64 vs. 47%, p < 0:001).
The prevalence of menopausal symptoms by
menopausal status group is presented in Table 3.
Peri- and postmenopausal women had signifi-
cantly higher frequencies of insomnia, arthralgia,
vaginal dryness, hot flushes and night sweats
compared with premenopausal women (p < 0:05;
v2 test). Except for frequent urination, which was
most severe for perimenopausal status (p ¼ 0:004),
postmenopausal women had higher frequencies for
the above symptoms.












Physical functioning 90.4 (12.8) 86.8 (15.6) 86.6 (17.4) 0.0001 0.002
Role limitation due to
physical problem
81.8 (31.8) 74.9 (36.9) 73.0 (36.8) 0.005 0.0002
Bodily pain 80.0 (18.9) 77.4 (19.1) 77.3 (19.7) 0.02 0.05
Vitality 66.4 (18.1) 65.1 (18.3) 63.7 (20.4) 0.44 0.09
Social functioning 86.5 (14.3) 84.5 (16.5) 85.0 (16.1) 0.13 0.45
Role limitation due to
emotional problem
82.5 (32.1) 78.8 (35.2) 77.3 (36.3) 0.11 0.05
Mental health 72.9 (15.9) 71.2 (16.7) 70.3 (18.2) 0.12 0.05
General health perceptions 66.2 (20.4) 63.2 (21.6) 61.5 (22.3) 0.04 0.007
HADS score 7.9 (5.5) 7.7 (6.0) 7.6 (5.4) 0.33 0.88
a Statistical analysis was performed using the Kruskal–Wallis test with Bonferroni’s correction for multiple comparisons, a p-value of
less than or equal to 0.017 was considered statistically significant.
bNone of the scores between perimenopausal and postmenopausal status achieve statistical significance, and were not listed.
HADS – hospital anxiety and depression scale.
Table 3. Menopausal symptoms experienced during the
2 weeks prior to study
Symptoms Menopausal status p-Value
Pre- (%) Peri- (%) Post- (%)
Insomnia 45.3 51.8 58.1 0.002
Headaches 42.3 41.6 36.2 0.281
Dizzy spells 38.6 38.9 42.4 0.575
Backaches 37.4 38.7 42.4 0.419
Arthralgia 29.8 35.2 38.6 0.028
Fatigue 30.1 33.0 33.3 0.504
Frequent
urination
23.5 32.7 25.2 0.004
Myalgia 25.1 26.0 26.2 0.928
Vaginal dryness 11.0 17.1 24.4 0.000
Hot flushes 8.4 14.3 16.7 0.000
Night sweats 3.1 7.8 11.4 0.000
p-Value derived using the v2 test, comparing the distribution of
subjects with and without symptoms for different menopausal
status.
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The impact of menopausal-symptom category
on QOL scores was also investigated. A breakdown
of mean SF-36 scores for different menopausal-
symptoms categories across the eight health-related
SF-36 domains is presented in Table 4. Signifi-
cantly lower SF-36 scores were observed when
comparing women with menopausal symptoms
and those without (p < 0:0001). Further, this pat-
tern was consistent across all eight of the health-
related dimensions. Additional analysis revealed a
similar pattern for SF-36 profiles with respect to the
presence of menopausal symptoms in each category
after controlling for menopausal status. Consis-
tently lower SF-36 scores were determined for each
menopausal status group where patients had all
four categories of menopausal symptoms. Further,
significantly lower SF-36 scores were noted for
women who presented with vasomotor symptoms,
despite controlling for the presence of insomnia
symptoms (all p O 0.01, except role limitation due
to emotional problem p=0.02).
Premenstrual syndrome
Overall, 44.4% of the enrolled women had PMS.
A significantly higher frequency of menopausal
symptoms (all p < 0:001, except vaginal dryness
p ¼ 0:003) and lower SF-36 scores (all p O
0.0001) were observed when comparing women
with PMS discomfort to those without.
The odds ratios for PMS relative to all 11
menopausal symptoms were between 1.5 and 2.4,
with 95% confidence intervals excluding 1. This
indicated that the likelihood of having menopausal
symptoms was significantly higher for PMS suf-
ferers.
Finally, the significantly lower SF-36 scores
demonstrated for women who had symptoms in
each of the four menopausal categories (compared
with those who did not) were consistent with the
scores for those with and without PMS (all
p < 0:01, except for role limitation due to emo-
tional problem vs. vasomotor symptoms without
PMS, p ¼ 0:12).
Discussion
This study investigated a large community-based
sample. Analysis of the results revealed that scores
for both the physical and psychological compo-
nents of QOL were worse for postmenopausal
Table 4. Mean SF-36 score (standard deviation) comparing status for individual menopausal-symptoms category across health-related
SF-36 domains
Vasomotor Psychosomatic Physical Urovaginal
Yes No Yes No Yes No Yes No
N=193 N=1163 N=995 N=357 N=745 N=611 N=481 N=875
Physical functioning 82.7 89.7 87.3 92.8 85.3 92.9 85.3 90.5
(19.4) (13.5) (15.4) (11.0) (16.2) (11.3) (17.6) (12.5)
Role limitation due
to physical problem
62.4 80.7 74.4 89.1 70.8 87.1 68.3 83.5
(41.2) (32.6) (36.2) (25.7) (37.5) (28.0) (39.7) (30.0)
Bodily pain 70.1 80.2 75.6 87.8 72.4 86.5 74.1 81.2
(20.1) (18.7) (19.1) (16.2) (19.0) (16.3) (19.8) (18.4)
Vitality 56.8 66.9 62.6 73.8 61.3 70.7 60.0 68.5
(18.8) (18.3) (18.9) (15.4) (18.7) (17.3) (19.2) (17.7)
Social functioning 79.8 86.7 84.0 90.6 82.8 89.2 81.6 87.9
(18.7) (14.4) (15.8) (12.0) (16.2) (13.3) (17.8) (13.2)
Role limitation due
to emotional problem
68.6 82.4 76.8 91.0 76.0 86.0 71.9 85.1
(41.1) (32.1) (36.1) (23.2) (36.3) (29.7) (38.1) (30.3)
Mental health 65.5 73.0 69.6 78.3 69.0 75.5 67.8 74.1
(17.1) (16.3) (16.8) (14.3) (16.6) (16.0) (17.1) (15.9)
General health
perceptions
54.5 66.1 60.8 74.9 58.9 71.3 57.7 68.1
(22.6) (20.6) (21.1) (17.9) (21.0) (19.4) (22.4) (19.6)
Significant differences were demonstrated for QOL for each of the menopausal-symptoms categories comparing location (p < 0.0001;
Wilcoxon rank-sum test).
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women than for premenopausal women. Accord-
ing to Ware et al. [11] a decrement of five points or
more is clinically relevant. This criterion was ful-
filled for both role limitation due to physical and
emotional problems. Although a bigger impact on
QOL was associated with presence of chronic ill-
ness, our results still support the proposition that
QOL is lower for peri- and postmenopausal women
in comparison to premenopausal women. The fact
most of the postmenopausal women in our study
were within 3 years of menopause, may explain
why SF-36 scores did not differ significantly be-
tween peri- and postmenopausal women.
Menopausal transition was associated with
several physical and psychological changes that
may impact women’s health outcomes. Several
researchers have suggested that the menopausal
transition leads to significant decreases in physical
activity, energy expenditure, resting metabolic rate
and fat-free mass [22, 23]. The findings of this
study are consistent with those reported by Sowers
et al. [24], who demonstrated that even at the rel-
atively young age of 40–55 years, approximately
one-fifth of women self-reported limited physical
function. Our study also revealed that the impact
of menopause on physical-role function appears to
be independent of age and BMI. The poorer
physical-role function scores for perimenopausal
and postmenopausal women may be associated
with estrogen deficiency.
Compromised psychological well-being during
the menopausal transition has long been noted.
Nevertheless, the relationship is still controversial
[25, 26]. Our study demonstrated that menstrual
status is related to SF-36 role limitation due to
emotional problem score but not HADS score.
This discrepancy may be due to variations in
sensitivity and the dimensions of the mental scales.
Of these so-called menopausal symptoms, only
the frequencies of insomnia, arthralgia, and vaso-
motor and urogenital symptoms were significantly
higher for the peri- and postmenopausal groups
compared to the premenopausal group. Further,
the magnitude of the impact of these menopausal
symptoms on QOL score was striking. Those
women with the menopausal symptoms listed
above had marked impairment in all eight domains
surveyed by the SF-36. Although the methodology
of the study of Daly et al. [1] has been criticized
[27], our results support their finding that QOL
may be compromised for women with menopausal
symptoms. Our results are also in line with Lede-
sert et al. [2] who demonstrated that poorer re-
ported QOL scores for postmenopausal women
were explained by climacteric complaints. Never-
theless, we cannot rule out the possibility that
poorer health status may predispose a woman to
menopausal symptoms, rather than the contrasting
notion that menopausal symptoms predispose fe-
males to poorer health status.
Disruption of sleep is a common problem, which
has been associated with hot flushes [28]. It has
been suggested that many of the mood changes
associated with menopause may result from the
sleep disruptions associated with hot flushes during
the night [29, 30]. Our results confirm that women
with vasomotor symptoms are more likely to have
insomnia, however, the lower QOL score in this
group cannot be explained by insomnia alone.
It is interesting to note that PMS had a signifi-
cant impact on QOL score and menopausal
symptoms for our subjects. Although retrospective
diagnosis of PMS may be biased by recall error,
our results are consistent with earlier findings of
an association between vasomotor symptoms and
previous PMS [31, 32]. The mechanisms of PMS
are still controversial, however. It has been sug-
gested that women with a history of PMS have
increased sensitivity to hormonal changes [33].
There is also a socially mediated model, in which
stressful life circumstances, menstrual socialization
and depressed mood are associated with PMS [34].
The hypothalamic-pituitary-adrenal axis and auto-
nomic nervous system also play important roles in
PMS symptoms [35]. The association of PMS with
higher frequency of menopausal symptoms and
lower QOL scores may imply that women who are
sensitive to hormonal changes are at increased risk
for menopausal symptoms and reduced QOL
during the menopausal transition. It is also possi-
ble that women prone to PMS usually have higher
levels of life stress, causing the increased symptom
frequency and reduced QOL.
The prevalence of vasomotor symptoms report-
ed for Taiwanese is markedly lower than that re-
ported in the western literature [14]. This finding
is similar to other Asian studies [36]. Taiwanese
women perceive menopause as a normal life pro-
cess and are more positive about menopause than
western women [37]. This is the first report of QOL
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for Asian women in midlife. It is not possible to be
sure if the results can be extrapolated to other racial
and ethnic groups, however. The positive aspects of
menopausal transition for Taiwanese women not-
withstanding, the impact on QOL cannot be over-
looked for these traditional Chinese women.
In conclusion, it was determined in this cross-
sectional population-based study of rural Chinese
women thatQOLwas poorer for naturally peri- and
postmenopausal women within the first 3 years of
menopause compared to premenopausal women,
and that menopausal symptoms may have a signif-
icant impact on QOL. The validity of any extra-
polation of our results to late-menopausal women
is indeterminate, however, since most of our post-
menopausal women were within 3 years of meno-
pause and the incidence and severity of menopausal
symptoms are greatest in the first 2 years of meno-
pause after which they gradually decrease.
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